Accelerating CNS Clinical Trials & Detecting Earlier Efficacy Signals Through More Sensitive Digital Biomarkers
2:00 pm - Wednesday 2nd December 2026
- Explore how digital biomarkers are being established alongside standard clinical scales to measure disease progression and drug effect in Parkinson’s, Huntington’s disease, and other rare neurological conditions including their implementation as primary endpoints in Phase II and secondary endpoints in Phase III programmes
- Discover how sensitive, longitudinal digital biomarker measures can enable Phase II studies to run two to three times faster with two to three times smaller sample sizes, reducing clinical trial costs while detecting earlier signals of drug efficacy
- Examine how virtual control arms generated from natural history study data can identify early efficacy signals in Phase I studies
